CareCloud, Inc. (CCLD) is a Nasdaq-listed, AI-powered healthcare technology and revenue cycle management (RCM) company serving medical practices and health systems. Its analyst coverage is thin and highly dispersed. The highest verified current target is $8.00, reiterated by Maxim Group with a Buy rating in November 2026. The lowest is $2.50, set by Roth MKM with a Hold rating after trimming its prior $3.25 target. Additional coverage clusters near $6.00, and depending on which current targets are counted, published averages run from roughly $5.25 to $6.13.
Because the analyst count is small, no single figure should be treated as a firm Street consensus. The $6.00 central target used here is the rounded arithmetic mean of the verified targets reviewed, which span $2.50 to $8.00. That unusually wide range reflects genuine disagreement: bullish analysts emphasize improving margins and AI-driven efficiency, while more cautious analysts point to decelerating revenue and a still-small equity base. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
With the stock trading near $2.42 in mid-November 2026, reaching $6.00 implies upside of approximately 148% — a very large move for a company of this size. CareCloud reported its most profitable quarter in company history for the period ended September 30, 2026, with revenue of $33.7 million (up 9% year over year), GAAP net income of $4.7 million (up 54%), GAAP EPS of $0.10, and adjusted EBITDA of $9.9 million (up 28%). It was the company's 10th consecutive quarter of positive GAAP net income.
However, the path to $6.00 would likely require more than profitability alone. Management reaffirmed, rather than raised, full-year 2026 guidance of $128 million to $132 million in revenue, $29 million to $31 million in adjusted EBITDA, and $0.20 to $0.23 in GAAP EPS. A meaningful re-rating would probably depend on sustained revenue acceleration and a broader recognition of the company's margin improvements.
CareCloud trades well below its 52-week high, which is reported in the range of roughly $3.80 to $4.00. Recent support has formed near the $2.00 to $2.16 area, while resistance sits near $2.60 to $3.00. A sustained move toward $6.00 would first require reclaiming the $4.00 zone and then the psychological $5.00 level — milestones that imply a substantial change in market structure and investor sentiment for a stock of this size.
Analyst price targets typically reflect a research horizon of about 12 months, though the small and dated nature of this coverage makes that assumption less reliable here. Investors should watch quarterly revenue trajectory and any change to guidance, further disclosure on AI-driven margin gains, free cash flow and debt reduction, and the rollout of the compliance and enterprise AI offerings. Any additional analyst initiations or target revisions would also be important given how few cover the stock. From what I see, monitoring these factors closely will be key.
In my analysis of names with thin coverage and high volatility, I’ve found Tickeron’s AI Daily Buy/Sell Signals helpful for tracking momentum shifts. These signals use artificial intelligence to monitor thousands of stocks and ETFs continuously, generating Buy, Sell, or Hold signals based on changing market conditions, technical behavior, and AI-driven analysis. For a micro-cap like CareCloud, this kind of automated monitoring can surface potential turning points more efficiently than manual review alone, helping investors stay on top of developments as they unfold.
The $6.00 target is a calculated average of a wide analyst range from $2.50 to $8.00, and it represents a roughly 148% move from a price near $2.42. Reaching it would require CareCloud to sustain its record profitability while reaccelerating revenue growth and winning broader market confidence in its AI-driven operating model. The strongest supports are the company's margin expansion and improving efficiency, while the principal obstacles are decelerating top-line growth, unchanged guidance, and a fragile balance sheet. Given the divided analyst views and the stock's small size, the outcome remains highly uncertain, and investors should monitor revenue momentum and cash generation closely rather than treat the target as a forecast.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Financial analyst and market blogger with expertise in equity research, fundamental analysis, and macroeconomic trends. I regularly publish coverage on individual stocks, ETFs, and sector developments — combining rigorous financial analysis with clear, engaging writing for a broad investment audience.
CCLD moved above its 50-day moving average on November 05, 2026 date and that indicates a change from a downward trend to an upward trend. In 37 of 43 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
The Momentum Indicator moved above the 0 level on November 04, 2026. You may want to consider a long position or call options on CCLD as a result. In 77 of 91 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for CCLD just turned positive on October 29, 2026. Looking at past instances where CCLD's MACD turned positive, the stock continued to rise in 36 of 45 cases over the following month. The odds of a continued upward trend are 80%.
The 10-day moving average for CCLD crossed bullishly above the 50-day moving average on November 10, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 11 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 69%.
Following a +5.58% 3-day Advance, the price is estimated to grow further. Considering data from situations where CCLD advanced for three days, in 190 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The 10-day RSI Indicator for CCLD moved out of overbought territory on November 13, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 20 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CCLD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
CCLD broke above its upper Bollinger Band on November 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for CCLD entered a downward trend on November 04, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Seasonality Score of 34 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. CCLD’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 76 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.617) is normal, around the industry mean (4.523). P/E Ratio (32.857) is within average values for comparable stocks, (12.601). Projected Growth (PEG Ratio) (0.314) is also within normal values, averaging (1.536). Dividend Yield (0.000) settles around the average of (0.011) among similar stocks. P/S Ratio (0.699) is also within normal values, averaging (6.105).
The Tickeron SMR rating for this company is 76 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CCLD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 97, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a provider of medical billing and transcription services
Industry ServicestotheHealthIndustry